In October 2010 Mabion S.A. gained nearly 40 mln PLN funds for the development of MabionCD20. It has been the highest funds obtained by Polish company from the beginning of the 1.4-4.1 PO Innovative Economy Programme. Funds gained were used for the completion of the development of product. The total value of the project is 74.8 mln PLN.
In February 2012. Mabion S.A. signed a project agreement for the implementation of an innovative technology "double cutting". This is a technology of obtaining modern hormone analogs of human insulin. The project was financed from the 1.4-4.1 PO Innovative Economy Programme. The amount of funding amounted to more than 24 mln PLN and the total value of the project is 40 397 000 mln PLN.
In November of 2013 Mabion gained 10 mmln PLN funding to support the clinical development of the drug MabionHER2, form the programme INNOMED. The total value of the project is nearly 24 mln PLN. The project funds are to be settled by May 2017.